BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23991977)

  • 1. Serum CEA level change and its significance before and after Gefitinib therapy on patients with advanced non-small cell lung cancer.
    Qin HF; Qu LL; Liu H; Wang SS; Gao HJ
    Asian Pac J Cancer Prev; 2013; 14(7):4205-8. PubMed ID: 23991977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer.
    Kamiya K; Watanabe M; Kohno M; Izumi Y; Horinouchi H; Kawamura M; Shimada N; Nomori H
    Respirology; 2011 Aug; 16(6):976-82. PubMed ID: 21651645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
    Fiala O; Pesek M; Finek J; Benesova L; Minarik M; Bortlicek Z; Topolcan O
    Anticancer Res; 2014 Jun; 34(6):3205-10. PubMed ID: 24922695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].
    Xu CA; Su H; Liu JL; Li L; Zou HW
    Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):436-41. PubMed ID: 21875484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
    J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.
    Jung M; Kim SH; Hong S; Kang YA; Kim SK; Chang J; Rha SY; Kim JH; Kim DJ; Cho BC
    Yonsei Med J; 2012 Sep; 53(5):931-9. PubMed ID: 22869475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer.
    Okamoto T; Nakamura T; Ikeda J; Maruyama R; Shoji F; Miyake T; Wataya H; Ichinose Y
    Eur J Cancer; 2005 Jun; 41(9):1286-90. PubMed ID: 15939264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer.
    Ni XF; Wu P; Wu CP; Ji M; Wu J; Gu XF; Jiang ZX
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):e22-30. PubMed ID: 24889374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].
    Zhao LD; Li JL; Wang Y; Wang B; Wang HY; Hao XZ; Cui CX; Zhang XR; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):217-21. PubMed ID: 21575523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer.
    Wang Z; Zhu XX; Wu XH; Li B; Shen TZ; Kong QT; Li J; Liu ZB; Jiang WR; Wang Y; Hou B
    Am J Clin Oncol; 2014 Apr; 37(2):148-53. PubMed ID: 23211223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study.
    Arrieta O; Villarreal-Garza C; Martínez-Barrera L; Morales M; Dorantes-Gallareta Y; Peña-Curiel O; Contreras-Reyes S; Macedo-Pérez EO; Alatorre-Alexander J
    BMC Cancer; 2013 May; 13():254. PubMed ID: 23697613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
    Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer.
    Lin WC; Chiu CH; Liou JL; Chen YM; Perng RP; Tsai CM
    Lung Cancer; 2006 Nov; 54(2):193-9. PubMed ID: 16996166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
    Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
    Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
    Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
    Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
    Koyama N; Uchida Y
    Anticancer Res; 2013 Nov; 33(11):5083-9. PubMed ID: 24222153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
    Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
    Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib.
    Chiu CH; Shih YN; Tsai CM; Liou JL; Chen YM; Perng RP
    Lung Cancer; 2007 Aug; 57(2):213-21. PubMed ID: 17449138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
    Jiang AG; Chen HL; Lu HY
    BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.